VIRAL Vs. NON-VIRAL GENETIC ENGINEERING OF T CELLS
- Christina Slater
- Jan 2, 2023
- 1 min read
Updated: Jan 10, 2023
Series in collaboration with the American Society of Gene & Cell Therapy
Combining Oncolytic Viruses and CAR-T Therapies
Saul Priceman,City of Hope, CA
Virus-free gene editing of T cells
Dimitrios Wagner, Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, Germany
Considerations for engineering allogeneic cell therapies
Marco Alessandrini, Antion Bioscience